NR4A1 and non-Hodgkin lymphoma: Taselisib is being investigated in a clinical trial for several types of advanced or metastatic solid tumor and non-Hodgkin’s lymphoma (NHL), together with hormone receptor-positive breast cancer (NCT01296555) [139].